Nadya Tsurayya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nadya Tsurayya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ario Betha Juanssilfero
Research Center for Applied Microbiology-Research Organization for Life Sciences and Environment, The National Research and Innovation Agency (BRIN), Jakarta Pusat, Indonesia
1 shared publication - Asep Bayu
Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN), Bogor, Indonesia
1 shared publication - Elin Julianti
School of Pharmacy, Bandung Institute of Technology, Jl. Ganesha No.10, Bandung 40132, Indonesia
1 shared publication - Fauzia Izzati
Department of Pharmacology and Toxicology, The University of Toronto, Toronto, Ontario, Canada
1 shared publication - Ikram Ammar Abrian
School of Pharmacy, Bandung Institute of Technology, Jl. Ganesha No.10, Bandung 40132, Indonesia
1 shared publication - Marlia Singgih Wibowo
School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia
1 shared publication
Latest Publications
- Open Access
- 12 January 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (1) , 67
Secondary Metabolites from Marine-Derived Fungi and Actinobacteria as Potential Sources of Novel Colorectal Cancer Drugs
Colorectal cancer is one of the most common cancers diagnosed in the world. Chemotheraphy is one of the most common methods used for the pharmacological treatment of this cancer patients. Nevertheless, the adverse effect of chemotherapy is not optimized for improving the quality of life of people who are older, who are the most vulnerable subpopulation. This review presents recent updates regarding secondary metabolites derived from marine fungi and actinobacteria as novel alternatives for cytotoxic agents against colorectal cancer cell lines HCT116, HT29, HCT15, RKO, Caco-2, and SW480. The observed marine-derived fungi were from the species Aspergillus sp., Penicillium sp., Neosartorya sp., Dichotomomyces sp., Paradendryphiella sp., and Westerdykella sp. Additionally, Streptomyces sp. and Nocardiopsis sp. are actinobacteria discussed in this study. Seventy one compounds reviewed in this study were grouped on the basis of their chemical structures. Indole alkaloids and diketopiperazines made up most compounds with higher potencies when compared with other groups. The potency of indole alkaloids and diketopiperazines was most probably due to halogen-based functional groups and sulfide groups, respectively.
- 12 January 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (1) , 67
Open AccessSecondary Metabolites from Marine-Derived Fungi and Actinobacteria as Potential Sources of Novel Colorectal Cancer Drugs
Colorectal cancer is one of the most common cancers diagnosed in the world. Chemotheraphy is one of the most common methods used for the pharmacological treatment of this cancer patients. Nevertheless, the adverse effect of chemotherapy is not optimized for improving the quality of life of people who are older, who are the most vulnerable subpopulation. This review presents recent updates regarding secondary metabolites derived from marine fungi and actinobacteria as novel alternatives for cytotoxic agents against colorectal cancer cell lines HCT116, HT29, HCT15, RKO, Caco-2, and SW480. The observed marine-derived fungi were from the species Aspergillus sp., Penicillium sp., Neosartorya sp., Dichotomomyces sp., Paradendryphiella sp., and Westerdykella sp. Additionally, Streptomyces sp. and Nocardiopsis sp. are actinobacteria discussed in this study. Seventy one compounds reviewed in this study were grouped on the basis of their chemical structures. Indole alkaloids and diketopiperazines made up most compounds with higher potencies when compared with other groups. The potency of indole alkaloids and diketopiperazines was most probably due to halogen-based functional groups and sulfide groups, respectively.